The acquisition adds a differentiated BTK inhibitor to the pipeline, enabling parallel development in food allergy, CSU, and MS, funded by $200M in new financing. Phase II studies are set to begin in 2026, targeting large unmet needs with a once-daily oral therapy.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.